

29 July 2024

Appointment of Dr Tony Keating as Executive Director & Resignation of Dr Tom Young

Highlights:

- **Appointment of Dr Tony Keating as part time Executive Director, effective 29 July 2024**
- **Dr Keating brings extensive experience as a healthcare executive, having co-founded ResApp Health and led it through commercialisation, culminating in a \$180m acquisition by global biopharmaceutical company Pfizer in 2022**
- **Along with his track record in commercialising AI-based digital health technology, Dr Keating brings advanced knowledge of the US regulatory landscape and strong networks in the global healthcare industry**
- **Appointment strengthens the composition of the Board ahead of pending results of TRI's comprehensive Phase 2 SAMDE study for TrivarX's proprietary MEB-001 algorithm which assists with the effective screening of a current Major Depressive Episode (cMDE)**
- **Resignation of Dr Thomas Young as Non-Executive Director, effective 29 July 2024**

Perth, Australia, and Minneapolis, USA: TrivarX Limited ('the Company') (ASX: TRI) is pleased to advise that it has further strengthened its Board with the appointment of Dr Tony Keating as part time Executive Director, effective 29 July 2024. Concurrently, the Company advises that Dr Tom Young will resign from his position as Non-Executive Director.

Dr Keating brings a wealth of executive experience in the global healthcare industry, where he has successfully combined strong technical expertise with a demonstrated track record in bringing innovative health solutions through to commercialisation.

Prior to his appointment to the Board of TrivarX, Dr Keating was the co-founder and Chief Executive Officer of ResApp Health, a digital health company which successfully developed a groundbreaking smartphone technology for accurately diagnosing respiratory diseases based on cough analysis.

Dr Keating led the ResApp team through the commercialisation of the company's technology, commencing with a successful R&D phase through to global regulatory approvals and commercial partnerships, before overseeing the sale of the company to Pfizer in 2022 for \$180m. Following the acquisition, he transitioned to the role of Vice President at Pfizer to manage the integration of ResApp's business.

Prior to co-founding ResApp, Dr Keating was the Director of Commercial Engagement at UniQuest, the commercialisation arm of The University of Queensland (UQ) which specialises in industry-university collaborations for the UQ's in-house network of 7,000 world-class researchers.

Dr Keating holds a PhD in Mechanical Engineering from The University of Queensland, and an Executive Certificate of Management and Leadership from the MIT Sloan School of Management.

The Board and management would also like to take this opportunity to thank Dr Young for his service to the Company. During his tenure, Dr Young has been instrumental in TrivarX's clinical trial design, progress and regulatory engagement. The Company wish him well for his future endeavours.

For personal use only

ASX ANNOUNCEMENT



Non-Executive Chairman, David Trimboli said: *“As TrivarX advances its proprietary technology suite of AI-based mental health solutions, we are pleased to welcome an industry leader of Tony’s calibre to the Board. Dr Keating’s track record in commercialising AI-based digital health solutions speaks for itself, and he brings several key attributes which will complement the existing strengths of the Board, including advanced knowledge of the US regulatory landscape and strong commercial networks in the global healthcare industry. We look forward to working with Tony to oversee the strategic direction of the business having recently completed TrivarX’s comprehensive Phase 2 SAMDE Study.”*

Incoming Executive Director, Dr Tony Keating said: *“I’m excited by the opportunity to join the TrivarX Board at this pivotal moment. Developing tools like TrivarX’s MEB-001 to diagnose, monitor and manage mental health conditions is essential for providing timely support, reducing stigma, and improving overall quality of life for people with mental health disorders. I look forward to working closely with the TrivarX team to advance our technology suite through to commercialisation and make a meaningful impact on people’s lives.”*

Director appointment and resignation remuneration details:

As part of his resignation and subject to shareholder approval at the Company’s Annual General Meeting (**AGM**) to be held on or before 30 November 2024, Dr Young has agreed to take his outstanding consultant fees and accrued director fees in the form of ordinary fully paid shares (**Shares**) in the Company. Approval will be sought to issue the Shares at an issue price per share equal to the VWAP of TrivarX (ASX:TRI) calculated for the 15 days prior to the day of the AGM. Dr Young’s outstanding fees are as follows:

- Consultant fees - US\$55,000 (to be converted to AUD using the RBA USD:AUD foreign exchange rate on 29 July 2024); and
- Director fees - AU\$39,354.84.

Dr Tony Keating will receive a salary of A\$96,000 per annum (gross) inclusive of superannuation consisting of:

- AU\$60,000 per annum to be paid in arrears on an annual basis and subject to shareholder approval at the Company’s AGM, ordinary fully paid shares at an issue price equal to the VWAP of TrivarX (ASX:TRI) calculated for the 10 days prior to the day of the AGM; and
- AU\$36,000 per annum paid in cash, monthly in arrears.

This announcement is authorised for release by the Board of Directors of TrivarX Limited.

ENDS

Investor Enquiries:

Henry Jordan – Six Degrees Investor Relations

Henry.jordan@sdir.com.au

+61 431 271 538

About TrivarX Limited:

TrivarX (ASX: TRI) (OTCPINK: MDBIF) is a mental health technology company pioneering the use of objective measures to aid in the early detection and screening of mental health conditions. The Company was founded in Australia, with offices located in Perth (WA) and Minneapolis (MN, USA). TrivarX is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on www.otcmarkets.com and www.asx.com.au